We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+19.76%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$1.95B
AUM Growth
-$39.6M
Cap. Flow
-$245M
Cap. Flow %
-12.56%
Top 10 Hldgs %
59.19%
Holding
59
New
12
Increased
4
Reduced
29
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$128M
2
CLYM
Climb Bio
CLYM
+$21.8M
3
FTH
Faeth Therapeutics
FTH
+$16.7M
4
SYRE icon
Spyre Therapeutics
SYRE
+$16.4M
5
ANL
Adlai Nortye Group ADS
ANL
+$13.1M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$77.7M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$41.7M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$25.9M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$23.4M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.09%
2 Financials 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$9.63B
$214M 10.98%
640,000
-245,500
-28% -$77.7M
BBOT
2
BridgeBio Oncology
BBOT
$701M
$136M 6.98%
17,878,594
– –
PBLS
3
Parabilis Medicines Inc
PBLS
$4.83B
$126M 6.47%
+4,615,612
New +$128M
RAPP
4
Rapport Therapeutics
RAPP
$2.34B
$111M 5.67%
2,657,521
-300,000
-10% -$11M
ERAS icon
5
Erasca
ERAS
$6.31B
$110M 5.63%
6,000,000
+200,000
+3% +$2.86M
EWTX icon
6
Edgewise Therapeutics
EWTX
$4.64B
$102M 5.23%
2,510,000
-750,000
-23% -$25.9M
EYPT icon
7
EyePoint Inc
EYPT
$386M
$100M 5.13%
7,000,000
-1,265,000
-15% -$16.9M
ALMS
8
Alumis Inc
ALMS
$2.9B
$92.5M 4.74%
3,285,596
-663,645
-17% -$15.4M
ABVX
9
Abivax
ABVX
$9.89B
$90M 4.61%
675,000
-85,000
-11% -$9.62M
DNTH icon
10
Dianthus Therapeutics
DNTH
$5.92B
$73.1M 3.75%
750,000
-200,000
-21% -$17.5M
DRUG
11
Bright Minds Biosciences
DRUG
$714M
$63.2M 3.24%
900,000
-159,331
-15% -$12.5M
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.28B
$62.4M 3.2%
3,205,433
-1,275,000
-28% -$23.1M
BIOA
13
BioAge Labs
BIOA
$443M
$58.6M 3%
2,390,605
-500,000
-17% -$9.03M
ORKA
14
Oruka Therapeutics
ORKA
$6.03B
$50.8M 2.6%
533,340
– –
ANL
15
Adlai Nortye Group ADS
ANL
$890M
$45.7M 2.34%
3,978,229
+1,080,372
+37% +$13.1M
BBIO icon
16
BridgeBio Pharma
BBIO
$15B
$41M 2.1%
550,000
-300,000
-35% -$21M
TNGX icon
17
Tango Therapeutics
TNGX
$3.94B
$40.6M 2.08%
1,300,000
-125,000
-9% -$3.09M
BHVN icon
18
Biohaven
BHVN
$2.33B
$38.8M 1.99%
2,610,000
+850,000
+48% +$9.15M
AGMB
19
AgomAb Therapeutics NV
AGMB
$649M
$32M 1.64%
2,465,348
– –
MBX
20
MBX Biosciences
MBX
$3.03B
$30.4M 1.56%
550,000
-570,000
-51% -$19.9M
CLYM
21
Climb Bio
CLYM
$837M
$27.5M 1.41%
+2,106,000
New +$21.8M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$899M
$26.9M 1.38%
2,150,000
-1,750,000
-45% -$23.4M
DMRA
23
Damora Therapeutics
DMRA
$1.79B
$26M 1.33%
1,000,000
-525,000
-34% -$12.7M
PHVS icon
24
Pharvaris
PHVS
$2.48B
$25.9M 1.33%
750,000
-250,000
-25% -$7.56M
CRBP icon
25
Corbus Pharmaceuticals
CRBP
$211M
$22M 1.13%
2,344,971
– –
1
2 3

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Cormorant Asset Management held 59 positions worth $1.95B, down 2% from $1.99B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $245M in Q2 2026, closing 9 positions and reducing 29 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $41.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Parabilis Medicines Inc worth $126M.

  • Cormorant Asset Management's largest Q2 2026 buy was Parabilis Medicines Inc: 4,615,612 shares worth $126M.
  • Cormorant Asset Management added most to Faeth Therapeutics in Q2 2026, an estimated $16.7M increase.
  • Cormorant Asset Management's biggest Q2 2026 reduction was Praxis Precision Medicines, cutting an estimated $77.7M.
  • Cormorant Asset Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.7M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.95B portfolio in Q2 2026.
  • Cormorant Asset Management opened 12 new positions and closed 9 in Q2 2026.
  • Cormorant Asset Management's portfolio value fell 2% quarter-over-quarter to $1.95B.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.